The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC) (BIGHPANC)
The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma
Sponsor: Centre Leon Berard
This observational or N/A phase trial investigates Pancreas Adenocarcinoma and is currently ongoing. Centre Leon Berard leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Jan 2025 — Present [monthly]
Unknown
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Jan 2023 [monthly]
Recruiting
▶ Show 9 earlier versions
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Feb 2021 — Nov 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2019 — Nov 2020 [monthly]
Recruiting
-
Aug 2018 — Jun 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Leon Berard
For direct contact, visit the study record on ClinicalTrials.gov .